Business
-
Chance Pharmaceuticals has announced a new agreement giving Huadong Medicine the rights to commercialize Chance Pharma’s CXG87 formoterol / budesonide DPI in mainland China. Financial details of the agreement were not disclosed. In March 2025,… Read more . . .
-
Lupin has announced that it will invest $250 million over 5 years to build a new 70,000 sq ft inhaler manufacturing facility in Coral Springs, Florida, USA, where the company opened an inhalation research center… Read more . . .
-
Italian biotech NanoPhoria Bioscience announced that it has raised €83.5 million in Series A financing to support development of its NP-MP1 “lung-to-heart nano-in-micro technology.” The company notes that the €83.5 million funding is the largest… Read more . . .
-
AeroRx Therapeutics announced that it has closed a $21 million Series A financing to support continued development of the company’s AERO-007 indacaterol / glycopyrrolate inhalation solution for the treatment of COPD. In 2022, AeroRx announced… Read more . . .
-
Orexo announced that the US Biomedical Advanced Research and Development Authority (BARDA) has awarded the company $8 million to support the development of OX390, a new chemical entity formulated for nasal delivery for the reversal… Read more . . .
-
Leyden Laboratories announced that it has raised €30 million in equity financing from the European Innovation Council (EIC) Fund and Invest-NL to support development of its PanFlu intranasal human monoclonal antibody for the prevention and… Read more . . .
-
AstraZeneca has announced that it will sell the Airsupra albuterol / budesonide MDI directly to US patients through a web site called AstraZeneca Direct starting October 1, 2025. According to the company, patients with a… Read more . . .
-
ReCode Therapeutics said that the Cystic Fibrosis Foundation will provide an additional $3 million for development of RCT2100 inhaled mRNA therapy for CF and that the company has closed a funding of more than $29… Read more . . .
-
Tonix Pharmaceuticals has announced plans for a Phase 2 trial of its TNX-2900 intranasal magnesium-potentiated oxytocin in patients with Prader-Willi syndrome (PWS). According to Tonix, the FDA has already cleared the company’s IND for a… Read more . . .
-
Gossamer Bio, which is developing inhaled dry powder seralutinib, announced a deal with Samsara BioCapital giving the company an option to acquire Respira Therapeutics along with Respira’s RT234 vardenafil DPI. On signing, Gossamer will issue 2.5 million… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden